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Abstract: Alteplase (recombinant tissue plasminogen activator) has been used in the   treatment of 
acute ischemic stroke for 10 years. The application of this drug is considered safe and   effective. 
However, alteplase is also associated with side effects. The author is reporting on an unusual 
side effect of angioedema that is triggered by alteplase. Angioedema occurs through alteplase 
according to this study at a frequency of 5.88% (95% confidence interval: 0.98% to 28.76%). 
In this case immunoglobulin G was slightly increased. The relative risk to get an angioedema 
compared between the two genders is elevated in men 3.3 (95% confidence interval: 0.15% 
to 71.90%; P = 0.4423), who were 3.3 times more likely to suffer than women. The use of 
angiotensin-converting-enzyme (ACE) inhibitors is considered a   possible risk factor for the 
occurrence of angioedema with concomitant administration of tissue plasminogen activator. 
The angioedema may occur with use of alteplase at any time, so treatment with this drug must 
always be carried out in intensive care and doctors must be ready for intubation if necessary.
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Introduction
Recombinant tissue plasminogen activator (rt-PA) has been used for a long time in the 
therapy of acute ischemic insult. The application of intravenous thrombolysis for ischemic 
stroke has already been established as a standard treatment throughout the world. For 
various reasons, however, only a small proportion of ischemic stroke patients were treated 
with alteplase,1 so we know little about the side effects of this drug. Hypersensitivity to 
alteplase is uncommon and has been estimated to occur in less than 0.02% of patients 
who receive it for the treatment of acute myocardial infarction.2 However, anaphylactic 
reaction by alteplase may also occur more in acute ischemic stroke patients.2 A little 
known complication of acute stroke treatment with systemic rt-PA thrombolysis is oro-
lingual angioedema. This has occurred in 2% of patients for thrombolysis.3 There is an 
increased risk for the occurrence of angioedema during the therapy with alteplase,3,6,10 
especially in patients receiving angiotensin-converting enzyme inhibitors. Angiodema 
by alteplase is usually only reported on from larger clinics so this present study is unique 
because it has been performed in a peripheral hospital with a small stroke unit. This means 
that the results of this study, combined with those of previous studies, can offer greater 
insight by discussing a broader   spectrum than was previously available.
Case presentation
Among the patients given recombinant tissue plasminogen activator intravenously for 
acute ischemic stroke in this hospital (Vinzentius-Hospital, Landau, Germany), one 
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had lingual angioedema. This was a   63-year-old patient, who 
was at home in bed at 11 pm. His wife came into the bedroom 
and saw her husband lying motionless and mute in bed. She 
was terrified and immediately alerted the emergency services. 
The emergency doctor was on site as soon as possible. He 
diagnosed a right hemiparesis and dysphasia, possibly due 
to a stroke. After arriving at hospital, a cranial CT to exclude 
intracranial hemorrhage was performed. After exclusion of 
contraindications for thrombolytic therapy, it was suggested 
that lysis with alteplase could solve a left-sided media infarc-
tion with flaccid hemiparesis on the right, right-sided facial 
paralysis, dysphasia, and dysphagia. His bleeding was within 
normal limits. Additionally, and unrelated to the onset of 
the current problem, he had arterial hypertension, diabetes 
mellitus type 2, obesity, and chronic obstructive pulmonary 
disease. The man was taking a beta-blocker, angiotensin-
converting-enzyme (ACE) inhibitor and, if needed for pain 
relief, non-steroidal anti-inflammatory drugs (NSAIDs), 
diuretics, inhalants, and benzodiazepine. The patient met the 
criteria for intravenous alteplase treatment of acute ischemic 
stroke (within a window of time of 80 minutes) and was given 
0.9 mg/kg alteplase after a 10% bolus initially with the remain-
ing drug infused over 60 minutes. Due to his high body weight 
(120 kilograms), the maximum dose of 90 mg of alteplase 
was prescribed.
After intravenous administration of 80 mg alteplase, 
the patient suddenly had trouble breathing. His tongue was 
swollen and he fought for breath. His entire body was blue 
and gray in color. He had to be reanimated and intubated 
  immediately. The alteplase infusion was stopped at this time. 
The patient then received high-dose cortisone, antihistamine, 
and catecholamine. Later, he had to be tracheotomized. 
The next day, a head computerized tomography (CT) scan 
was performed and no hemorrhage could be seen but a big 
demarcation of the left middle cerebral artery was inspected. 
The patient ultimately spent 18 days in intensive care. He 
recovered from the angioedema, but his right hemiparesis, 
speech disturbance, and dysphagia remained.
After this event, all records of patients with stroke after 
thrombolytic therapy were examined for similar events in 
order to avoid angioedema by alteplase in the future.
The aim of this study was to determine the incidence 
of angioedema by alteplase in a peripheral hospital with a 
minor stroke unit in comparison to other published results. 
Furthermore, this study aims to answer the question whether 
the occurrence of angioedema through alteplase is depen-
dent on other factors, such as the number of thrombolysis 
occurrences.
Materials and methods
This is a retrospective study of clinical data belonging to 
730 patients. The criterion for inclusion was all patients had 
cerebral ischemia followed by thrombolysis. The author 
found a total of 17 patients that fit this criterion. All stroke 
patients in this study had their heads scanned by CT or mag-
netic resonance imaging (MRI). These patients were also 
examined by a neurologist. A CT scan of all patients was done 
in order to exclude a brain hemorrhage, prior to thrombolysis. 
All contraindications before lysis were excluded. The lysis 
therapy was carried out within the time frame of 3 hours 
for all stroke patients. After performing the thrombolysis, 
all patients were checked by a brain CT.
Results
The author thoroughly examined records of 730 patients 
after cerebral ischemia that underwent thrombolysis. After 
further research, the author found just 17 ischemic stroke 
patients who had undergone alteplase treatment. These 
consisted of eight men 47.06% (95% confidence interval: 
+/−23.73%, 23.33% to 70.79%) and nine women 52.94% 
(95% confidence interval: +/−23.73%, 29.21% to 76.67%) 
(Figure 1). These patients all had cerebral ischemia and severe 
clinical symptoms and were treated by lysis with alteplase 
within the therapeutic time frame of 3 hours. The average age 
of these patients was 69.94 years with a standard deviation of 
11.82 years. A 63-year-old male patient had an angioedema 
with macroglossia during the treatment with alteplase in this 
hospital. The immunoglobulin E of this patient was within 
the reference range of immunoglobulin E (0–150 U/mL). His 
immunoglobulin E was 5.4 U/mL. The immunoglobulin G 
from this patient with macroglossia during treatment with 
alteplase was slightly increased at 17.4 g/L at a reference 
range from 7 to 16 g/L. The immunoglobulin M from this 
patient was within the normal range.
statistical analysis
The author measured the relative chance of cases having 
a positive outcome for both sexes with angioedema and 
without side effects. The proportion of cases having a posi-
tive outcome in angioedema under treatment with alteplase 
was 3.3 (95% confidence interval: 0.15% to 71.90%), (P = 
0.4423) between male and female. The odds of getting an 
angioedema under alteplase in two groups of men and women 
was 3.8 (95% confidence interval: 0.13% to 107.32%), (P = 
0.4335). The disease prevalence in angioedema under treat-
ment with alteplase was 5.88% (95% confidence interval: 
0.98% to 28.76%).
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The sensitivity, specificity, as well as disease prevalence 
were expressed as percentages for interpretation. The sensitiv-
ity is the probability that a test result will be positive when an 
angioedema under alteplase is present. The specificity is the 
probability that a test result will be negative when an angioe-
dema under alteplase is not present. The sensitivity and the 
specificity were 100%.
The two-sided significance of independence by Fisher’s 
exact test was calculated for angioedema by alteplase in the 
thrombolysis of patients with acute ischemic stroke. The 
two-sided significance was P-value of 0.471.
Discussion
Although the application of tissue plasminogen activator has 
been established as a standard therapy for ischemic stroke 
globally, it is known that a small proportion of patients are 
currently treated with thrombolytic drugs.1
It was remarkable to learn that only a small number 
of therapies use alteplase. According to the results of this 
study, the occurrence of angioedema as a side effect by the 
administration of alteplase does not depend on the number 
of thrombolysis occurrences.
Allergic reactions to thrombolysis can occur but are most 
commonly seen during therapy with streptokinase.4,5 Allergic 
reactions may also occur as reported in rare cases in the treat-
ment of myocardial infarction with alteplase.5
The aforementioned orolingual angioedema by alteplase 
was reported in recent studies.3 The prevalence of the 
  disease was increased to three times in this study of angioe-
dema under treatment with alteplase, as compared with 
other studies. The frequency of side effects under alteplase 
is the same in the present study as it is in studies published 
in other literature.6 Hill and colleagues reported in their 
work the similar prevalence of reaction with orolingual 
angioedema after alteplase treatment of stroke.6 In view 
of these studies, the incidence of orolingual angioedema 
under treatment with alteplase of ischemic stroke seems to 
undergo a significant variations.
Immunoglobulin G or M were found to be increased in the 
serum some days or weeks after therapy with alteplase.7
In this case, immunoglobulin G from this patient 
with macroglossia during treatment with alteplase was 
slightly increased. The immunoglobulin M from this patient 
was within the normal range.
The immunoglobulin E antibody was found in the 
serum of one patient with anaphylaxis under treatment 
with alteplase.8 The immunoglobulin E was normal in this 
study.
The angioedema as a side effect of alteplase seems to arise 
rapidly even during treatment, as in this case. Also, in the two 
patients studied by Hill and his colleagues, the angioedema 
occurred within 1 hour.2
Male 47%
Female 53%
Figure 1 The gender distribution of thrombolysis in 17 ischemic stroke patients with alteplase treatment.
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A possible cause of orolingual angioedema by alteplase 
is thought to be the concomitant use of ACE inhibitors, as 
suggested in various scientific literature. Risk of angioedema 
by alteplase was associated with angiotensin-converting 
enzyme inhibitors with a relative risk of 13.6%, such as Hill 
and his colleagues described.6
Also Krmpotic and Fernandes described an increased risk 
of anaphylaxis in patients concomitantly being treated with 
angiotensin-converting enzyme inhibitors, as illustrated in a 
case report describing a patient who experienced an urticarial 
rash, hypotension, tachycardia, orolingual angioedema, and 
airway obstruction following intravenous administration of 
alteplase.9 Possible pharmacologic interactions resulting in 
excessive serum bradykinin and subsequent systemic hyper-
sensitivity responses are discussed.9
Okada reported a 75-year-old woman with an orolingual 
angioedema considered as a complication associated with 
alteplase and taking ACE inhibitors.10
Also, the patient in this study took an ACE inhibitor to con-
trol blood pressure. An interaction between his ACE inhibitor 
and the treatment with alteplase is assumed to be likely.
Conclusion
Orolingual angioedema is a potentially life-threatening 
complication of treatment with alteplase in acute ischemic 
stroke. This complication can occur under treatment at any 
time. Therefore, the administration of this drug is carried 
out in intensive care. The advice, according to the findings 
of this study, is the introduction of a Guedel airway tube in 
the mouth of the patient with acute ischemic stroke prior to 
the thrombolysis with alteplase for at least four hours with 
the readiness of an imminent possible intubation.
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